Product image of Medifolin (Calcium Folinate) supplied by GNH India

Medifolin

Active Ingredient:
Calcium Folinate
Origin:
EU

Medifolin (Calcium Folinate)

Calcium folinate, the active ingredient in Medifolin, is a folate analog presented as an oral tablet for oral use. It is used to mitigate methotrexate toxicity, enhance 5‑fluorouracil efficacy, and treat folate deficiency in patients receiving chemotherapy or with low folate levels and is indicated for patients requiring folate rescue during high‑dose chemotherapy protocols.

GNH India supplies Medifolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Laboratório Medinfar - Produtos Farmacêuticos, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Medifolin (calcium folinate) is used in therapeutic areas that involve antifolate chemotherapy and folate metabolism disorders.

  • Methotrexate toxicity: Provides rescue therapy to reduce toxic effects of methotrexate.
  • 5‑Fluorouracil‑based cancer treatment: Enhances efficacy by stabilizing intracellular folate pools.
  • Folate deficiency: Restores normal folate levels in patients with documented deficiency.

How It Works

  • Calcium folinate supplies 5‑formyl‑tetrahydrofolate, a reduced folate that bypasses dihydrofolate reductase inhibition. By entering the folate cycle downstream of the blocked step, it restores nucleotide synthesis, supports DNA replication, and reduces the cytotoxic impact of antifolate agents such as methotrexate, thereby protecting normal cells while allowing chemotherapy to remain effective.

Side Effects

Adverse reactions may occur with calcium folinate therapy.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Transient elevation of liver enzymes: mild, usually reversible.
  • Headache: occasional mild headache.
  • Rash: mild skin erythema or itching.
  • Diarrhea: mild gastrointestinal upset.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response requiring immediate medical attention.
  • Severe hepatic dysfunction: marked increase in liver enzymes or jaundice.
  • Bone marrow suppression: pancytopenia or severe neutropenia.
  • Renal toxicity: acute kidney injury in susceptible individuals.
  • Stevens‑Johnson syndrome: rare severe skin reaction.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Renal function monitoring: assess creatinine clearance and adjust dose if needed.
  • Hepatic function monitoring: check liver enzymes periodically.
  • Dose adjustment in renal impairment: reduce dose or increase interval for patients with reduced clearance.
  • Hypersensitivity awareness: discontinue if signs of allergic reaction appear.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Calcium folinate may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid)

  • High‑dose folic acid supplementation: may diminish the intended rescue effect of calcium folinate.
  • Trimethoprim: can exacerbate folate deficiency and reduce efficacy.
  • Phenytoin: may lower folate levels and counteract therapeutic benefit.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may affect renal clearance of calcium folinate.
  • Cytarabine: potential additive myelosuppression.
  • Carboplatin: possible increase in hematologic toxicity.

Frequently Asked Questions

Medifolin contains calcium folinate and is employed as a rescue agent for methotrexate toxicity, as an enhancer of 5‑fluorouracil‑based chemotherapy, and to correct folate deficiency in patients who require additional folate support during cancer treatment or who have documented low folate levels.

Calcium folinate provides 5‑formyl‑tetrahydrofolate, a reduced folate that bypasses the dihydrofolate reductase block created by antifolate drugs. This restores folate‑dependent nucleotide synthesis, allowing normal cells to continue DNA replication while reducing the toxic impact of agents such as methotrexate.

The dose of Medifolin is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and concurrent chemotherapy regimen. Healthcare providers determine the appropriate amount and dosing schedule for each patient.

Safety data for calcium folinate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Medifolin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Unlike simple folic acid, calcium folinate is a reduced folate that can bypass dihydrofolate reductase inhibition, making it effective as a rescue agent during antifolate chemotherapy. Standard folic acid does not provide the same protective effect against methotrexate‑induced toxicity.

Medifolin should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat, and direct sunlight to maintain stability and potency.

Medifolin is supplied as an oral tablet and should be taken with water, preferably on an empty stomach or as directed by the prescribing physician. The exact timing relative to chemotherapy agents is determined by the treating oncologist.

Serious adverse events include severe allergic reactions (anaphylaxis), marked liver enzyme elevation leading to hepatic dysfunction, bone marrow suppression resulting in pancytopenia, acute kidney injury, and rare severe skin reactions such as Stevens‑Johnson syndrome. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to calcium folinate or any component of the tablet should avoid it. Those with severe renal impairment, uncontrolled hepatic disease, or a history of severe allergic reactions to folate analogues should not receive Medifolin unless a specialist determines that the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Calcium Folinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT